Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05432336
Other study ID # APHP220259
Secondary ID 2021-A02587-34
Status Recruiting
Phase
First received
Last updated
Start date November 21, 2023
Est. completion date May 2025

Study information

Verified date March 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Etienne CANOUI, MD
Phone 0033158414267
Email etienne.canoui@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the impact of different technique to optimize the microbiological diagnosis of the COI. - Metagenomic for the endophtalmitis - Multiplex polymerase chain reaction for corneal abscesses


Description:

Microbiological diagnosis of complex ocular infection (COI) (i.e: endophtalmitis and corneal abscess) is a current challenge. Indeed, endophtalmitis are often germ-free because a lack of microbiological diagnosis due to small volume to analyze and a complex site to attain. The microbiological etiologies of corneal abscesses are more frequently identified. Since few years, new molecular tools are developed in infectious diseases to optimizing the microbiological diagnosis. The investigators implemented these techniques in our hospital to optimize the microbiological diagnosis of complex ocular infection (COI). Thus, endophtalmitis benefit, when the volume of the ocular sample is sufficient, of molecular techniques (16s PCR and metagenomic shotgun). Corneal abscesses could shortly benefit of multiplex PCR in order to reduce the time to diagnosis. The impact and accuracy of these techniques is unknown.


Recruitment information / eligibility

Status Recruiting
Enrollment 149
Est. completion date May 2025
Est. primary completion date November 2024
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patient - Patient presenting or having presented a clinical suspicion of complex ocular infection requiring a sample for microbiological diagnosis: - Corneal abscess requiring hospitalization - Any suspicion of endogenous or exogenous endophthalmitis. - Patient not opposed to participating in the research Exclusion Criteria: - Patient under guardianship or curatorship - Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
NGS for endohtalmitis / Multiplex PCR for keratitis
For endophtalmitis : optimizing culture and NGS will be realized For keratitis: Multiplex PCR will be added on ocular samples

Locations

Country Name City State
France Equipe mobile d'infectiologie, Cochin hospital Paris IDF

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positivity rates of COI samples according to the new protocol Before/after type comparison. Comparison of the positivity rates of COI samples according to the new protocol: (i) for endophthalmitis performing a vitreous puncture (PV) or an anterior chamber puncture (PCA) optimized with modification of microbiological techniques (culture on enriched medium alone associated with shotgun metagenomics), (ii) for severe corneal abscesses, addition to standard microbiological techniques of molecular biology tests (multiplex PCR and / or metagenomics).
An COI will be considered with a positive microbiological diagnosis after multidisciplinary concertation considering the different results
2 weeks after taking samples
Secondary Microbiological diagnosis of the infection Analysis of a prospective cohort of COI At the end of the follow up: 18 months
Secondary Time to microbiological diagnosis according to the different technic Analysis of a prospective cohort of COI At the end of the follow up: 18 months
Secondary Accuracy of the different technics according to the gold standard (microbiological culture) Analysis of a prospective cohort of COI At the end of the follow up: 18 months
Secondary Visual acuity Evaluation of visual acuity at the end of treatment and the cure rate. The investigators hypothesized that the improvement of the microbiological diagnosis allows an improvement of the therapeutic management and thus of the visual outcome. At the end of the follow up: 18 months
Secondary Cure rate Evaluation of visual acuity at the end of treatment and the cure rate. The investigators hypothesized that the improvement of the microbiological diagnosis allows an improvement of the therapeutic management and thus of the visual outcome. At the end of the follow up: 18 months
Secondary Modification or not of the anti-infectious treatment Analysis of the impact of microbiological diagnosis on the choice of anti-infectious molecules..
The investigators hypothesized that the improvement of the microbiological diagnosis and the implementation of the COI management bundle will induce a modification of the prescription of anti-infectious molecules. The investigators will realize a qualitative and quantitative analysis of prescribed anti-infective molecules
At the end of the follow up: 18 months
See also
  Status Clinical Trial Phase
Completed NCT00513734 - A Comparison of Hydrogel Dressings and Ocular Lubricants in the Prevention on Corneal Damage in the Critically Ill N/A
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Recruiting NCT06229379 - The Effects of a Large Language Model on Clinical Questioning Skills N/A
Completed NCT01268306 - Study of the Presence and Extent of Corneal Disturbance Associated With B+L Biotrue MPS Used With B+L PureVision Lenses Phase 4
Completed NCT01028027 - Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis Phase 3
Completed NCT04169061 - Impact of Acthar on Everyday Life of Participants With Severe Keratitis Phase 4
Completed NCT03237936 - Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis Phase 4
Completed NCT00001734 - Screening for NEI Clinical Studies N/A
Recruiting NCT05255107 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Phase 2/Phase 3
Recruiting NCT05255016 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers Phase 2/Phase 3
Terminated NCT05250583 - Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Treatment-Resistant Keratitis Phase 2
Recruiting NCT02865876 - Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis Phase 3
Terminated NCT02116062 - Robotic Surgery of the Ocular Surface N/A
Recruiting NCT00838422 - Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound N/A
Completed NCT00949468 - Microbiological Keratitis in a Countryside City of Brazil N/A
Completed NCT03586505 - Tolerance to Light for Patients Suffering From Keratitis N/A
Recruiting NCT04420962 - Automated Quantitative Ulcer Analysis Study
Completed NCT02186431 - Contact Lenses and Infiltrative Keratitis N/A
Completed NCT05538793 - Deep Learning for the Discrimination Among Different Types of Keratits: a Nationwide Study
Not yet recruiting NCT05689996 - Ozone-based Eye Drops as Adjuvant Therapy in Microbial Keratitis Phase 3